

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the present application.

IN THE CLAIMS:

1. (Previously Presented) An intraoral quickly disintegrating tablet comprising a cyclic GMP phosphodiesterase inhibitor and a saccharide selected from the group consisting of mannitol, xylitol, and erythritol,

wherein the saccharide is present in a ratio of 4 to 30 parts by weight to 1 part by weight of the cyclic GMP phosphodiesterase inhibitor.

2. (Original) The tablet as claimed in Claim 1, which further comprises a binder.

18-0428 3. (Original) A method for manufacturing the ^{tablet} ~~table~~ defined in claim 1, which comprises mixing a cyclic GMP phosphodiesterase inhibitor with a saccharide, kneading the mixture with an organic solvent, water or an aqueous organic solvent and subjecting it to a compression-molding.

4. (Original) The method as claimed in claim 3, which comprises filling the kneaded mixture in a mold and subjecting it

to a compression-molding with a film.

5. (Withdrawn) An intraoral quickly disintegrating tablet comprising a difficultly soluble pharmaceutical agent and a saccharide and further comprising at least one selected from surfactant and a water-soluble polymer.

6. (Withdrawn) A method for manufacturing the tablet as claimed in claim 5, which comprises dissolving a difficultly soluble pharmaceutical agent in an organic solvent or an aqueous organic solvent together with at least one selected from a surfactant and a water-soluble polymer, coating the solution on a filler or granulating it with a filler to obtain molded products, mixing a saccharide with them, adding an organic solvent, water or an aqueous organic solvent thereto, followed by kneading, and subjecting it to a compression-molding.

7. (Withdrawn) A method for manufacturing the tablet as claimed in claim 5, which comprises adding at least one selected from a surfactant and a water-soluble polymer and a saccharide to a difficultly soluble pharmaceutical agent, followed by mixing, adding an organic solvent, water or an aqueous organic solvent thereto, followed by kneading, and subjecting it to a compression-molding.

8. (Withdrawn) The method for manufacturing as claimed in claim 6, wherein the molded products are granules, fine granules or powder.

9. (Withdrawn) The method for manufacturing as claimed in claim 6, in which the granulation-molding is carried out, using a fluidized bed granulator, a tumbling granulator, an extrusion granulator or a spray-drying granulator.


10. (Withdrawn) The method for manufacturing as claimed in claim 6 or 7, which comprises filling the powder kneaded with the organic solvent, water or the aqueous organic solvent in a mold and subjecting it to compression-molding with a film in the compression-molding stage.

11. (Withdrawn) The tablet as claimed in claim 5, wherein the slightly soluble pharmaceutical agent is a cyclic GMP phosphodiesterase inhibitor.


12. (Currently Amended) The method for manufacturing as claimed in claim 6, wherein the slightly soluble pharmaceutical agent is a cyclic GMP phosphodiesterase ~~phosphodiesterase~~ inhibitor.

~~5~~^{13.} (Currently Amended) The tablet as claimed in any one of claims 1 ^{or} and 2 1, 2 and 11, wherein the cyclic GMP phosphodiesterase inhibitor is selected from the group consisting of:


5-[2-ethoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one represented by the formula (I)




1,3-dimethyl-6-(2-propoxy-5-methanesulfonamido phenyl)-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one represented by the formula (II)



2-(4-carboxypiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline represented by the formula (III)




(6*R*,12*aR*) -2,3,6,7,12,12*a*-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-*b*]-indol-1,4-dione represented by the formula (IV)



, and

(3*S*,6*R*,12*aR*) -2,3,6,7,12,12*a*-hexahydro-2,3-dimethyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-*b*]-indol-1,4-dione shown by the formula (V)




or a pharmacologically acceptable salt thereof.


14. (Cancelled).

6,15. (Currently Amended) The tablet as claimed in any one of
~~0408~~
claims 1 or 2 claim 14, wherein the cyclic GMP phosphodiesterase
inhibitor is a compound represented by the formula (VI) is
selected from the group consisting of:


4-(3-chloro-4-methoxybenzyl)amino-6-cyano-1-(4-
hydroxypiperidino)phthalazine hydrochloride represented by the
formula (IX)




4-(3-chloro-4-methoxyphenethyl)amino-6-cyano-1-(4-hydroxypiperidino)phthalazine hydrochloride represented by the formula (X)



4-[(3-chloro-4-methoxybenzyl)amino] -1-(2-hydroxy-7-azaspiro[3,5]non-7-yl)-6-phthalazine carbonitrile hydrochloride represented by the formula (XI)




1 - (2-hydroxy-7-azaspiro[3,5]non-7-yl)-4-[(4-methoxy-3-methylbenzyl)amino]-6-phthalazine carbonitrile hydrochloride represented by the formula (XII)




1 - [4-fluoro-4-(hydroxymethyl)piperidino]-4-[(4-methoxy-3-methylbenzyl)amino]-6-phthalazine carbonitrile hydrochloride

represented by the formula (XIII)




4-[(3-chloro-4-methoxyphenethyl)amino]-1-(2-hydroxy-7-azaspiro[3,5]non-7-yl)-6-phthalazine carbonitrile hydrochloride shown by the formula (XIV)



, and

4-[(3-chloro-4-methoxybenzyl)amino]-1-(3-oxo-2-oxa-8-

azaspiro[4,5]decen-8-yl)-6-phthalazine carbonitrile represented by the formula (XV)



16. (Canceled).

2-0498 7 17. (Previously Presented) The method for manufacturing as claimed in any one of claims 3 and 4, wherein the cyclic GMP phosphodiesterase inhibitor is selected from the group consisting of:

5-[2-ethoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one represented by the formula (I), and

a compound represented by the formula (VI),
or pharmaceutically acceptable salts thereof.